semaglutide patent expiration 2031 Off-patent in 2026: the next revolution in anti-obesity medications Overpatented 2025 – I-MAK

Reduced HRV during the early treatment phase is expected and typically normalizes during the adaptation phase

Positive topline data announced in April showed that the trial met its primary endpoints using both the treatment-regimen* and efficacy estimands

If you are healthy, your body makes what it needsprovided you feed it protein and get adequate sleep

These numbers exceeded the Phase 2 results, partly because the trial ran longer (68 weeks versus 48 weeks) and partly because the dose escalation schedule was refined

Lavin wasnt involved in the study

The identification of the pleiotropic SNP PMSnpB394 , associated with 14 vigor and longevity-related traits, highlights genomic regions of major effect influencing seed performance and viability